Focus: Vividion Therapeutics is a San Diego-based biotech company founded in 2023 leveraging proprietary screening technology to develop small-molecule oncology therapeutics. The company is currently public-stage with an early-stage pipeline focused on advanced solid tumors.
Profile data last refreshed 56m ago · AI intelligence enriched 3w ago
Stable — net -3 jobs in 30d
4 added, 7 removed. Backfill posture.
Vividion is a high-risk, early-stage biotech bet suited for scientists and engineers who value technological platform and early-stage IP upside over near-term financial visibility or clinical proof-of-concept.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Vividion Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Vividion Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo